Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy

In this review, we examine the literature supporting treatment decision making in the front-line and relapsed/refractory settings for patients with chronic lymphocytic leukemia (CLL). In the front-line setting, novel-agent-based approaches, including continuous Bruton tyrosine kinase (BTK) inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2022-02, Vol.82 (2), p.133-143
Hauptverfasser:	Roeker, Lindsey E., Thompson, Meghan, Mato, Anthony R.
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Antineoplastic Agents - therapeutic use Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell lymphoma Bruton's tyrosine kinase Cardiac arrhythmia Chemotherapy Chronic lymphocytic leukemia Cyclophosphamide Decision making Enzyme inhibitors Fludarabine Humans Hypertension Immunoglobulins Immunotherapy Inhibitors Internal Medicine Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - pathology Literature reviews Lymphatic leukemia Lymphocytes B Lymphoma Medicine Medicine & Public Health Patients Pharmacology/Toxicology Pharmacotherapy Phosphoinositide-3 Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Proto-Oncogene Proteins - antagonists & inhibitors Randomized Controlled Trials as Topic Recurrence Remission Review Article Rituximab Survival Targeted cancer therapy Tyrosine Variable region
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!